Semaglutide: The Peptide That Needed the Bloodstream

The short version

Semaglutide is a GLP-1 receptor agonist — a peptide engineered to mimic a gut hormone the body releases after eating. It could never simply be applied to skin: at 31 amino acids, it is roughly ten times larger than GHK-Cu and carries none of that tripeptide's measured skin-crossing behavior. Instead, it is FDA-approved as a once-weekly subcutaneous injection and, in a separate formulation, a once-daily oral tablet built around a specialized absorption enhancer.

The trial record is large. In the STEP 1 weight-management trial, once-weekly semaglutide produced markedly greater body-weight change than placebo over 68 weeks ^[11]. In SELECT, a trial of more than 17,000 adults with cardiovascular disease, it reduced major cardiovascular events relative to placebo ^[10]. In a more recent head-to-head trial, however, semaglutide was outperformed on weight loss by the newer dual-agonist tirzepatide ^[8]. This page describes what was studied and where; it recommends no dose and offers no medical advice.

What it is

Semaglutide is a 31-amino-acid synthetic analogue of human glucagon-like peptide-1 (GLP-1), sharing about 94% of its sequence with the native hormone. Two substitutions confer its defining property — resistance to rapid breakdown: at position 8, a naturally occurring amino acid is swapped for one that blocks the enzyme (DPP-4) that would otherwise clear it from the blood within minutes, and a second substitution at position 34 adds further stability. A fatty-acid side chain attached near the peptide's other end binds tightly and reversibly to albumin, the most abundant protein in blood plasma — an anchoring trick that shields the peptide from the kidneys and extends its circulating presence to roughly a week, the structural basis for once-weekly dosing.

The oral tablet formulation solves a completely different problem: getting a peptide through the stomach and gut wall at all. It is co-formulated with an absorption-enhancing molecule that briefly raises the pH across a small patch of stomach lining, and even then, oral bioavailability is only about 0.4 to 1 percent ^[12] — a striking contrast with GHK-Cu's directly measured skin permeability.

How it works

By activating GLP-1 receptors throughout the body, semaglutide does several things simultaneously. In the pancreas, it boosts insulin release from beta cells only when blood sugar is already elevated — a glucose-dependent mechanism that limits the risk of blood sugar dropping too low when the drug is used alone — while suppressing glucagon, the hormone that raises blood sugar. It also slows gastric emptying, which blunts post-meal glucose spikes and is a major contributor to the nausea some people experience.

Its weight effect is mostly a brain effect. Semaglutide reaches appetite circuits in the hypothalamus and brainstem, activating neurons that signal fullness and quieting neurons that drive hunger-seeking behavior. This reduces both how much people eat and, according to many patient reports, the background mental preoccupation with food some describe as 'food noise.' Because none of this pharmacology depends on the skin barrier at all, semaglutide's development effort went almost entirely into blood-borne delivery — an injectable with a week-long half-life, and an oral tablet engineered around the gut's own defenses — rather than any topical route.

What the research shows

Head-to-head against a dual agonist. A 2025 phase 3b trial directly compared semaglutide against the newer dual-receptor agonist tirzepatide in 751 adults with obesity over 72 weeks, at each drug's maximum tolerated dose. Tirzepatide produced significantly greater weight loss than semaglutide, a difference of roughly six and a half percentage points ^[8] — the most recent and direct comparison available, and one that places semaglutide as the benchmark a newer agent has since surpassed.

Weight management. In the STEP 1 trial of 1,961 adults with overweight or obesity and no diabetes, once-weekly semaglutide produced a mean body-weight change of about -14.9% at 68 weeks, versus -2.4% with placebo ^[11].

Cardiovascular outcomes. In SELECT, a trial of 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes, semaglutide reduced the combined risk of cardiovascular death, non-fatal heart attack, or non-fatal stroke by about 20% relative to placebo ^[10].

Kidney outcomes. In the FLOW trial of 3,533 adults with type 2 diabetes and chronic kidney disease, semaglutide reduced the risk of major kidney-disease events by about 24% relative to placebo ^[9].

Safety profile. A dedicated safety review characterizes semaglutide's overall risk-benefit balance as favorable in type 2 diabetes, dominated by mild-to-moderate, mostly transient gastrointestinal effects — nausea in roughly a third of patients — alongside an increased risk of gallbladder disease and pancreatic- and thyroid-cancer signals too infrequent to draw firm conclusions from ^[12].

Reported effects, cautions & safety

People using semaglutide describe a strikingly consistent cluster of effects in patient communities — anecdotal, not clinical evidence, compiled from patient-experience reporting rather than controlled trials.

Reported benefits: By far the most common description is a quieting of the constant background thinking about food — 'food noise' going quiet, often within the first week or two — alongside sharply reduced cravings for sugar and fried food. Weight loss follows steadily over months for most reviewers. People using it for type 2 diabetes commonly report markedly better blood-sugar readings, and a widely discussed secondary effect is reduced interest in alcohol.

Reported downsides: Nausea is the dominant complaint, mentioned by roughly a third of reviewers and typically peaking after each dose increase before easing. Distinctive sulfur-smelling burps are reported often, alongside constipation or diarrhea, acid reflux, and early fatigue on injection day. A subset describe hair shedding after months of rapid weight loss, generally attributed to the pace of loss itself rather than the drug.

Cited cautions from the clinical literature:

• Gastrointestinal intolerance during dose escalation is the leading clinical adverse effect and the main driver of discontinuation; it is dose-related and mostly transient ^[12].
• Thyroid C-cell tumors / MEN-2 (boxed warning). GLP-1 receptor agonists carry a boxed warning from rodent data; a personal or family history of medullary thyroid carcinoma or MEN-2 is treated as a contraindication, though the human risk signal is unconfirmed ^[12].
• Acute pancreatitis is a class warning, though quantifying the risk precisely is limited by how rarely it occurs ^[12].
• Gallbladder and biliary disease. An increased risk of gallstones is a confirmed clinical-trial and pharmacovigilance finding, attributed largely to the pace of weight loss itself ^[12].
• Weight regain after stopping. Because the drug's effect does not persist once discontinued, this is understood as a chronic therapy rather than a curative course, not something a person completes and keeps the result from indefinitely.

Where it fits in Research Peptide Fundamentals

Semaglutide is this desk's clearest illustration of a peptide built entirely around blood-borne delivery: no topical formulation exists because none of its receptor targets — pancreas, brainstem, hypothalamus — sit anywhere the skin can reach. Set beside GHK-Cu, whose entire relevance depends on a rare, measured skin-crossing behavior, and thymosin alpha-1, an immune-signaling peptide delivered by injection for an entirely different reason, semaglutide clarifies why 'how does it get in' is the organizing question of research peptide fundamentals rather than an afterthought. See the comparison page for the full picture.